about
Methylation profiling identified novel differentially methylated markers including OPCML and FLRT2 in prostate cancerPINCAGE: probabilistic integration of cancer genomics data for perturbed gene identification and sample classification.DNA Methylation-Guided Prediction of Clinical Failure in High-Risk Prostate CancerIdentification of Novel Epigenetic Markers of Prostate Cancer by NotI-Microarray AnalysisDNA Methylation-Mediated Downregulation of DEFB1 in Prostate Cancer CellsAberrant Protocadherin17 (PCDH17) Methylation in Serum is a Potential Predictor for Recurrence of Early-Stage Prostate Cancer Patients After Radical ProstatectomyIdentification of specific DNA methylation sites on the Y-chromosome as biomarker in prostate cancer.Epigenetics Reactivation of Nrf2 in Prostate TRAMP C1 Cells by Curcumin Analogue FN1Methylation of a panel of genes in peripheral blood leukocytes is associated with colorectal cancer.Epigenomic Regulation of Androgen Receptor Signaling: Potential Role in Prostate Cancer Therapy.RHCG and TCAF1 promoter hypermethylation predicts biochemical recurrence in prostate cancer patients treated by radical prostatectomy.The epigenetics of prostate cancer diagnosis and prognosis: update on clinical applications.Prognostic Value of Protocadherin10 (PCDH10) Methylation in Serum of Prostate Cancer Patients.The potential of DNA modifications as biomarkers and therapeutic targets in oncology.Biomarkers in localized prostate cancer.DNA Methylation and Urological Cancer, a Step Towards Personalized Medicine: Current and Future Prospects.Syndecan-1 up-regulates microRNA-331-3p and mediates epithelial-to-mesenchymal transition in prostate cancer.Aberrant gene-specific DNA methylation signature analysis in cervical cancer.Large-scale evaluation of SLC18A2 in prostate cancer reveals diagnostic and prognostic biomarker potential at three molecular levelsPITX3 promoter methylation is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients after radical prostatectomy.CDO1 promoter methylation is associated with gene silencing and is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients.LINE-1 methylation status in prostate cancer and non-neoplastic tissue adjacent to tumor in association with mortality.DNA methylation screening of primary prostate tumors identifies SRD5A2 and CYP11A1 as candidate markers for assessing risk of biochemical recurrence.Distinct DNA methylation alterations are associated with cribriform architecture and intraductal carcinoma in Gleason pattern 4 prostate tumors.Comprehensive Evaluation of TFF3 Promoter Hypomethylation and Molecular Biomarker Potential for Prostate Cancer Diagnosis and Prognosis.Identifying aggressive prostate cancer foci using a DNA methylation classifier.Heterogeneous patterns of DNA methylation-based field effects in histologically normal prostate tissue from cancer patients.The relative contribution of DNA methylation and genetic variants on protein biomarkers for human diseasesHigh levels of 5-hydroxymethylcytosine (5hmC) is an adverse predictor of biochemical recurrence after prostatectomy in ERG-negative prostate cancerAberrant Promoter Methylation of Protocadherin8 (PCDH8) in Serum is a Potential Prognostic Marker for Low Gleason Score Prostate Cancer.APC methylation predicts biochemical recurrence of patients with prostate cancer: a meta-analysis.Quantitative Proteomic Analysis of Human Airway Cilia Identifies Previously Uncharacterized Proteins of High Abundance.Clinical Significance of Measuring Global Hydroxymethylation of White Blood Cell DNA in Prostate Cancer: Comparison to PSA in a Pilot Exploratory Study.Promoter hypermethylation of SOX11 correlates with adverse clinicopathological features of human prostate cancer.Biomarker potential of ST6GALNAC3 and ZNF660 promoter hypermethylation in prostate cancer tissue and liquid biopsies.Epigenetic alterations in TRAMP mice: epigenome DNA methylation profiling using MeDIP-seq.RankProd Combined with Genetic Algorithm Optimized Artificial Neural Network Establishes a Diagnostic and Prognostic Prediction Model that Revealed C1QTNF3 as a Biomarker for Prostate Cancer.Dysregulation and prognostic potential of 5-methylcytosine (5mC), 5-hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC), and 5-carboxylcytosine (5caC) levels in prostate cancer
P2860
Q30764223-84C3F2F1-C749-4FEA-856D-09BD5363FC8AQ31035683-EF29BECA-E0E4-4DAB-AA32-8FD64944DEFBQ35667011-58299483-3466-4A7C-8130-8F96B8B6E7B8Q36150385-5FE3D59F-A64E-42D5-B31F-63578A783F0CQ36190050-061302F2-5D07-4432-BD8B-103D89047FC3Q36399311-B51F2475-CF77-4875-95B1-0E6AB7A6A8ABQ36562102-43CF0A4E-F786-4A3A-88A4-235F3DEE8FCAQ37114069-70B41F17-3C2C-475C-9F97-70F91BE1A41FQ37121671-279ACFD6-A20F-4EAE-BF34-EDC8EA37A0E4Q37629548-3811B7D7-8BF8-4167-AA6C-25243B1156F4Q37701479-62617746-F087-4F1B-9C4A-201E0212229CQ38269155-4E9ABD70-C05A-48EC-9076-2A77145FBD6CQ38544056-EC3BC5F1-15FA-4B1A-B422-33031CFA56D5Q38591064-A39D6EB5-D719-4C5A-B8F7-BD07E18FBE09Q38697114-D3EFE4F3-ACEE-4811-A4AF-D1BEBC75FD4FQ38833395-128FEE0E-2ACB-4FB0-B658-16C1130F43B8Q38844891-E5FB2B88-A4AD-41F1-925D-C121358452E0Q38870688-6C2512F7-FC40-470D-BE15-64B24111FF8BQ38904571-F06E2E7E-FF65-438D-8593-B75D9D4AD0C0Q39318240-D5BE485F-FA5E-49BA-BDE5-8D33A7886031Q39334962-8B8D0359-E85C-4C9E-B216-B004ED1C1D36Q40454546-69C0C5F4-E402-4438-93C5-D8C87A9DCB2FQ40581966-D551BD43-BBBE-4D4A-BA6D-40B87FBAA5B6Q40977912-1D5A8607-BD4C-45CA-A48D-B423A6E4D738Q41660235-6533D4C0-FBAD-4727-AE7D-5033084A5565Q42090895-B2017112-A9A7-4FD9-BE0D-1CE0BBF7E561Q42256326-B0EF72BA-4C21-459D-B002-1D304A7770B6Q42280727-B232C8AC-3617-42FB-8E41-D10E2CDFC201Q42539779-9D800772-ED81-4295-AEBA-0E09A7B11710Q42651317-3C84975E-2B66-4BFD-A85D-92F279ABC207Q43156796-32AACE2F-2D24-4F43-8E23-330BF4E1341DQ44870789-92FBBFB8-BD9C-463E-94D2-617D2444D94CQ47119316-07E60883-4AD4-4604-847D-481763F146A7Q47189377-DCE35963-1241-433F-8EA1-ED1FA0820D86Q49710514-748A07D1-C15D-4D59-8776-53005E8FECF5Q49985254-2F7618CF-6C5D-41C4-A0EB-A8B889AF48D6Q55401042-BA789E59-C01D-40FE-AF7F-7BB23A6DDAFCQ58797571-83EB18F2-3C9B-4073-BA6F-05075D00FEF9
P2860
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
Prognostic DNA methylation markers for prostate cancer.
@en
type
label
Prognostic DNA methylation markers for prostate cancer.
@en
prefLabel
Prognostic DNA methylation markers for prostate cancer.
@en
P2860
P921
P356
P1476
Prognostic DNA methylation markers for prostate cancer
@en
P2093
Siri H Strand
Torben F Orntoft
P2860
P304
16544-16576
P356
10.3390/IJMS150916544
P407
P5008
P577
2014-09-18T00:00:00Z